

## Andrew B. Wolf, MD

### Contact Information

---

12631 E. 17th Avenue  
Mail Stop B185  
Aurora, CO 80045

Phone: (303) 724-4328  
Fax: (303) 724-0985  
[andrew.wolf@cuanschutz.edu](mailto:andrew.wolf@cuanschutz.edu)

### Academic Appointments

---

Assistant Professor, Neuroimmunology Section 7/2023-Present  
Associate Program Director, Neuroimmunology Fellowship 7/2023-Present  
Department of Neurology, University of Colorado School of Medicine, Aurora, CO

### Program Affiliations

---

Rocky Mountain MS Center 7/2023-Present  
Neuroinfectious Diseases Group 7/2023-Present  
Global Neurology Group 7/2024-Present  
Department of Neurology, University of Colorado School of Medicine, Aurora, CO

### Education

---

Bachelor of Science (Physiology & Behavior) 5/2010  
Arizona State University, Tempe, AZ  
  
Master of Science (Neuroscience) 4/2016  
Doctor of Medicine (Clinical Medicine) 5/2018  
University of Colorado School of Medicine, Aurora, CO

### Clinical Training

---

Preliminary Internal Medicine Internship 6/2018-6/2019  
Neurology Residency 7/2019-6/2022  
Neurology Chief Residency 7/2021-6/2022  
Neuroimmunology Fellowship 7/2022-6/2023  
Department of Neurology, University of Colorado School of Medicine, Aurora, CO

### Medical Licensure

---

Colorado Medical Board, Physician Training License, #0007057 4/2018-2/2022  
Colorado Medical Board, Physician License, #0068220 2/2022-Present  
Wyoming Board of Medicine, Physician License #TL8245 5/2024-8/2024

### Board Certification

---

Neurology, American Board of Psychiatry and Neurology, Certificate 64702 9/2022-Present

## Clinical Privileges

---

Denver Health Medical Center, Denver, CO	7/2022-Present
University of Colorado Hospital, Aurora, CO	7/2022-Present
DAWN Clinic, Aurora, CO	7/2023-Present

## Peer-reviewed Articles

---

- 1.) Valla J\*, Yaari R\*, **Wolf AB**, Kusne Y, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010). Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the *APOE*  $\epsilon$ 4 allele, the major late-onset Alzheimer's susceptibility gene. *J Alzheimers Dis*, 22: 307-313. DOI 10.3233/JAD-2010-100129. \*Contributed equally
- 2.) **Wolf AB**, Braden BB, Bimonte-Nelson H, Kusne Y, Young N, Engler-Chiurazzi E, Garcia AN, Walker DG, Moses GSD, Tran H, LaFerla FM, Lue L, Emerson Lombardo N, Valla J (2012). Broad-based nutritional supplementation in 3xTG mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's intervention. *J Alzheimers Dis*, 24: 445-460. DOI 10.3233/JAD-2012-120478.
- 3.) Hardesty DA, **Wolf AB**, Brachman DG, McBride HL, Youssef EF, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2013). The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. *J Neurosurg*, 119: 475-481. DOI 10.3171/2012.12.JNS12414.
- 4.) **Wolf AB**, Caselli RJ, Reiman EM, Valla J (2013). *APOE* & neuroenergetics: an emerging paradigm in Alzheimer's disease. *Neurobiol Aging*, 34: 1007-1017. DOI 10.1016/j.neurobiolaging.2012.10.011.
- 5.) **Wolf AB**, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ (2013). Apolipoprotein E as a  $\beta$ -amyloid independent factor in Alzheimer's disease. *Alzheimers Res Ther*, 5: 38. DOI 10.1186/alzrt204.
- 6.) Snyder LA, **Wolf AB**, Oppenlander ME, Bina R, Wilson JR, Ashby L, Brachman DG, Coons SW, Spetzler RF, Sanai N (2014). The impact of extent of resection on malignant transformation of pure oligodendrogliomas. *J Neurosurg*, 120: 309-314. DOI 10.3171/2013.10.JNS13368.
- 7.) Oppenlander ME, **Wolf AB**, Snyder LA, Bina R, Wilson JR, Coons SW, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2014). An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *J Neurosurg*, 120: 846-853. DOI 10.3171/2013.12.JNS13184.
- 8.) **Wolf AB**, Lintz MJ, Costabile JD, Thompson JA, Stubblefield EA, Felsen G (2015). An integrative role for the superior colliculus in selecting targets for movements. *J Neurophysiol*, 114: 2118-2131. DOI 10.1152/jn.00262.2015.
- 9.) Perkins M, **Wolf AB**, Chavira B, Shonebarger D, Meckel JP, Leung L, Ballina L, Ly S, Jones TB, Vallejo J, Jentarra G, Valla J (2016). Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E  $\epsilon$ 4 Carriers. *J Alzheimers Dis*, 53: 95-106. DOI 10.3233/JAD-151205.

- 10.) Kusne Y\*, **Wolf AB\***, Townley K, Conway M, Peyman GA (2017). Visual system manifestations of Alzheimer's disease. *Acta Ophthalmol*, 95: 668-676. DOI 10.1111/aos.13319. \*Contributed equally
- 11.) **Wolf AB** & Felsen G (2019). How public health policy can be informed by neuroscience. *Behav Public Policy*, 3: 37-46. DOI 10.1017/bpp.2017.9.
- 12.) **Wolf AB**, Zhovtis Ryerson L, Pandey K, Vollmer T, Corboy JR, Alvarez E (2019). Rituximab-induced serum sickness in multiple sclerosis patients. *Mult Scler Relat Disord*, 36: 101402. DOI 10.1016/j.msard.2019.101402.
- 13.) **Wolf AB** & Alvarez E (2021). COVID-19 vaccination in patients with multiple sclerosis on disease-modifying therapy. *Neurol Clin Pract*, 11: 358-361. DOI 10.1212/CPJ.0000000000001088.
- 14.) **Wolf AB** & Alvarez E (2022). Ublituximab: A novel anti-CD20 therapy for multiple sclerosis. *touchREVIEWS in Neurology*. 18:117-121. DOI 10.17925/USN.2022.18.2.117.
- 15.) Shiao JC\*, **Wolf AB\***, Rabinovitch RA, Smith C, Kleinschmidt-Demasters BK, Ney DE (2022). Long-term control of primary cerebral ALH amyloidoma with focal radiation therapy. *Adv Radiat Oncol*, 100831. DOI 10.1016/j.adro.2021.100831. \*Contributed equally
- 16.) Shah AA\*, **Wolf AB\***, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR (2022). Challenging cases in neuroimmunology. *Semin Neurol*. 42: 695-707. DOI 10.1055/s-0042-1760100. \*Contributed equally
- 17.) Vollmer BL\*, **Wolf AB\***, Silau S, Corboy JR, Alvarez E (2022). Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis. *Front Neurol*, 799138. DOI 10.3389/fneur.2021.799138. \*Contributed equally
- 18.) **Wolf AB**, Palace J, Bennett JL (2023). Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). *Curr Treat Options Neuro*. 25: 437-453. DOI 10.1007/s11940-023-00776-1.
- 19.) **Wolf AB**, Money KM, Chandnani A, Daley CL, Griffith DE, Chauhan L, Coffman N, Piquet AL, Tyler KL, Zimmer S, Montague BT, Mann S, Pastula DM (2023). *Mycobacterium abscessus* meningitis associated with stem cell treatment during medical tourism. *Emerg Infect Dis*. 29: 23-0317. DOI 10.3201/2908.230317.
- 20.) **Wolf AB** & Corboy JR. Escalation to anti-CD20 treatment for multiple sclerosis following natalizumab-associated progressive multifocal leukoencephalopathy (2024). *Neurol Clin Pract*. 12: e200330. DOI 10.1212/CPJ.000000000000200330.

#### Letters to the Editor

---

- 1.) **Wolf AB**, Alvarez E, Corboy JR (2024). Comparative efficacy of disease-modifying treatments for relapsing multiple sclerosis - variations in real-world experience. *JAMA Neurol*. 81: 87, DOI 10.1001/jamaneurol.2023.4395

## Online Resources

---

1.) **Wolf AB** & Shah AA. Clinical trials in multiple sclerosis. MedLink Neurology. Updated 12/2023.

## Abstracts & Posters

---

1.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the common late-onset Alzheimer's disease susceptibility gene. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 5/2009.

2.) Valla J, Braden BB, Lind J, Young N, Engler L, Garcia A, Bowman B, **Wolf AB**, Page K, Kusne Y, Emerson Lombardo N, Bimonte-Nelson H. Comprehensive polynutrient dietary supplementation improves cognition in 3xTG mice. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.

3.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adults with the major Alzheimer's disease susceptibility gene. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.

4.) Emerson Lombardo N, Valla J, Braden BB, Lind J, Bimonte-Nelson H, Engler L, Garcia A, Young N, Auerbach SH, Bowman B, **Wolf AB**, Page K, Kusne Y, Volicer L. Nutritional supplement combination therapy improves cognition in 3xTG AD mice and will be tested in cognitively normal adults. Alzheimer's Disease International Annual Conference, Thessaloniki, Greece, 3/2010.

5.) **Wolf AB**, Valla J, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 5/2010.

6.) Valla J, **Wolf AB**, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. International Academy on Nutrition and Aging Annual Meeting, Santa Ana Pueblo, NM, 7/2010.

7.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. Arizona Neurosurgical Society Annual Meeting, Marana, AZ, 10/2011.

8.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. Society for Neuro-Oncology Annual Scientific Meeting, Garden Grove, CA, 11/2011.

9.) **Wolf AB**, Konkowski N, Henderson LB, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. International Conference on Brain Energy Metabolism: Bioenergetics of Neurological Disease and Aging, Pacific Grove, CA, 4/2012.

- 10.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 4/2012.
- 11.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 4/2012.
- 12.) **Wolf AB**, Konkowski N, Henderson L, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. Arizona Alzheimer's Consortium Annual Conference, Phoenix, AZ, 5/2012.
- 13.) Henderson LB, Allred R, **Wolf AB**, Alex M, Konkowski N, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. American Osteopathic Association Research Conference, San Diego, CA, 10/2012.
- 14.) **Wolf AB**, Felsen G. The function of GABAergic neurons in the superior colliculus during decision making. University of Colorado Neuroscience Program Annual Research Conference, Estes Park, CO, 11/2015.
- 15.) Essig J, **Wolf AB**, Felsen G. Functional role of inhibitory superior colliculus neurons in target selection. Society for Neuroscience Annual Meeting, San Diego, CA, 11/2016.
- 16.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. University of Colorado Department of Neurology Annual Research Retreat, Virtual, 6/2021.
- 17.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. American Neurological Association Annual Meeting, Virtual, 10/2021.
- 18.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies.ECTRIMS Annual Congress, Virtual, 10/2021.
- 19.) Crane PD, Ardakani R, Alvarez E, Chauhan L, Matthews E, Shah A, Pastula D, Money K, Piquet A, Tyler K, **Wolf AB**. Neuroinvasive West Nile virus associated with anti-CD20 treatment for CNS inflammatory diseases. ACTRIMS Annual Forum, West Palm Beach, FL. 3/2024.
- 20.) Rajarajan P, Quinn C, Gill A, Kopinsky H, Bacon T, **Wolf AB**, Murray J, Probasco J, Galetta K, Kantor D, Alvarez E, Coyle P, Conway S, Bhattacharyya S, Kister I. Multi-institutional study of neurologic outcomes in people with multiple sclerosis who are treated with immune checkpoint inhibitors for oncologic indications. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

21.) Ardakani R, Schmitt B, Carlson A, **Wolf AB**, Tyler K, Pastula D, Piquet A. JC virus granule cell neuronopathy mimicking paraneoplastic cerebellar degeneration. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

22.) Sollero CEV, Money KM, **Wolf AB**, Schmitt B, Sillau S, Nair KV, Piquet AL, Bennett JL, Carlson AM. Epidemiology of seropositive neuromyelitis optica spectrum disorder in a large US population. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

23.) Gill A, Quinn C, Rajarajan P, Gill A, Kopinsky H, **Wolf AB**, Bennett JL, Soares de Camargo C, Murray J, Conway S, Alvarez E, Coyle PK, Galetta K, Bhise V, Kantor D, Probasco J, Bhattacharyya S, Kister I. Disease Activity in People Living with MS and NMOSD Exposed to Immune Checkpoint Inhibitors: A Multi-Institutional Study. Consortium of Multiple Sclerosis Centers Annual Meeting, Nashville, TN. 4/2024.

24.) Ardakani R, Schmitt B, Carlson A, **Wolf AB**, Tyler K, Pastula D, Piquet A. JC virus granule cell neuronopathy mimicking paraneoplastic cerebellar degeneration. American Academy of Neurology Summer Conference, Atlanta, GA. 7/2024.

25.) Ardakani R, Crane PD, Alvarez E, Chauhan L, Matthews E, Shah A, Pastula D, Money K, Piquet A, Tyler K, **Wolf AB**. Neuroinvasive West Nile virus associated with anti-CD20 treatments. American Academy of Neurology Summer Conference, Atlanta, GA. 7/2024.

#### Certifications

---

Advanced Cardiac Life Support (ACLS), initial 5/2018

Basic Life Support (BLS), renewed 4/2022

CITI Program, renewed 2/2022

DEA Controlled Substance Registration Certificate, initial 6/2022

Expanded Disability Status Scale (EDSS), Level C, initial 4/2023

NIH Stroke Scale, renewed 5/2021

#### Memberships

---

American Academy of Neurology

American Neurological Association

Colorado Neurological Society

Siegel Rare Neuroimmune Association

#### Review Activity

---

Acta Ophthalmologica

Brain and Behavior

Cureus

JAMA Neurology

Journal of Clinical Pharmacy and Therapeutics

Journal of Neurology

Neuroimmunology Reports

Neurology

Neurology Clinical Practice

Neurology Education

Neurology Neuroimmunology & Neuroinflammation  
Neurology and Therapy

Grants

---

Project: Integration of multidomain digital biomarkers to detect worsening in multiple sclerosis  
Role: Co-PI (w/ Enrique Alvarez, MD/PhD)  
Source: Rocky Mountain Multiple Sclerosis Center  
Dates: 7/1/2023-7/1/2024  
Total Costs: \$9907

Project: Integration of multidomain digital and blood biomarkers to detect worsening in multiple sclerosis  
Role: PI  
Source: Mowry Family  
Dates: 12/1/2023-2/28/2025  
Total Costs: \$61496

Project: Integration of multidomain digital biomarkers to detect worsening in multiple sclerosis  
Role: Co-PI (w/ Enrique Alvarez, MD/PhD)  
Source: Brotherton Foundation  
Dates: 6/1/2024-6/1/2025  
Total Costs: \$15000

Clinical Studies

---

NCT03972306. A study to investigate the pharmacokinetics, safety, and tolerability of subcutaneous ocrelizumab administration in participants with multiple sclerosis (OCARINA I).  
Role: Sub-investigator, 2022-2023

NCT04544449. A study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult participants with primary progressive multiple sclerosis (FENtrepid).  
Role: Sub-investigator, 2022-present

NCT05503264. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with anti-N-methyl-D-aspartic acid receptor (NMDAR) or anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis (CIELO).  
Role: Sub-investigator, 2024-present

NCT04586010. A study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in relapsing multiple sclerosis (FENhance).  
Role: Sub-investigator, 2024-present

Teaching

---

University of Colorado Medical Students:

*IDPT 5022 Nervous System*

Neuropathology Lab – Neuroimmunology, 3/7/2022 (170 students, 4 hours)

Neuropathology Lab – Neuroimmunology, 3/6/2023 (170 students, 2 hours)

Neuropathology Lab – Neuroimmunology, 3/5/2024 (85 students, 2 hours)

*IDPT 7041 Neurologic Care*

Problem Based Learning – Acute Stroke, 9/3/2020 (12 students, 2 hours)

*IDPT 8037 Advanced Neuroscience*

Neuropathology Lab – Neuroimmunology, 11/16/2022 (170 students, 4 hours)

Neuroimmunology Cases, 12/15/2022 (170 students, 1 hour)

Neuroinflammation Cases, 10/25/2023 (170 students, 2 hours) w/ Kelli Money, MD/PhD

*IDPT 7006 Foothills Basecamp Transition to Clerkships*

Oral Presentations, 9/6/2023 (4 students, 2 hours)

*IDPT 8060 Alpine basecamp Transition to Advanced Clerkships*

Summarizing Evidence in Clinical Presentations, 1/31/2024 (8 students, 2 hours)

University of Colorado Neurology Residents:

*Didactic Lectures, ~24 residents, 1 hour*

Clinical Anatomy Cases – Spinal Cord, 12/2/2020

Neuroimmunology Board Review, 1/6/2021

Neuroradiology Cases – Neuroimmunology & Neuro-ophthalmology, 1/20/2021

Neuroradiology Cases – Neuroinfectious Disease, 6/16/2021 (w/ Madeline Garza, MD)

Neurological Emergencies in Pregnancy, 8/25/2021 (w/ Sharon Poisson, MD)

Burnout in Neurology: Definitions, Quantification, and Intervention, 9/1/2021

Epilepsy Neuroimaging, 10/27/2021

Epilepsy Clinical Cases, 10/27/2021 (w/ Dave Jeon, MD)

Pediatric Neuroimmunology, 1/12/2022

Neuroimmunology Board Review, 1/19/2022

Neuroradiology Cases – Neurodegenerative Disease, 5/11/2022

Neuro-oncology Board Review, 5/18/2022

Neurological Emergencies in Pregnancy, 8/24/2022 (w/ Sharon Poisson, MD)

Pediatric Neuroimmunology, 11/30/2022

Neurological Emergencies in Pregnancy and the Postpartum Period, 8/23/2023

Neuroradiology: MS, NMOSD, and MOGAD, 11/15/2023 (w/ Justin Honce, MD)

*Team-Based Learning, ~24 residents, 2 hours*

Neuroimmunology, 12/5/2023

University of Colorado Neuroimmunology / Neuroinfectious Disease Fellows:

Leukodystrophies, Mimicry & Misdiagnosis of Multiple Sclerosis, 8/16/2023

Epstein-Barr Virus & Multiple Sclerosis, 5/29/2024

Educational Materials

---

Neurology Residency Survival Guide – Neuroimmunology, 6/2021 (w/ Anthony Declusin, MD)

Practical Overview of Multiple Sclerosis Diagnosis & Management, revised 6/2024



## Mentorship

---

### Neuroimmunology Fellows (as Associate Program Director):

Molly Moehlman, MD 2023-2024 (now faculty at Cincinnati Children's Hospital Medical Center)

### Developing our Clinical Skills (DOCS) Students:

Hanna Vanderpool, MSI 2023-2024

## Clinical Supervision

---

### University of Colorado Medical Students:

University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 7/2023-present

DAWN Clinic, ~1 evening monthly, 7/2023-present

### University of Colorado Neurology Residents:

Denver Health neuroimmunology clinic, ~6 half-days yearly, 7/2022-present

University of Colorado Hospital continuity clinics, ~1 half-day monthly, 7/2023-present

University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 7/2023-present

DAWN Clinic, ~1 evening monthly, 7/2023-present

### University of Colorado Neuroimmunology Fellows:

University of Colorado Hospital neuroimmunology clinic, ~4 half-days monthly, 7/2023-present

### University of Colorado Neuroinfectious Diseases Fellows:

University of Colorado Hospital neuroimmunology clinic, ~4 half-days monthly, 7/2024-present

## Intramural Presentations

---

### University of Colorado Neurology Grand Rounds:

Clinical Case Review, 4/12/2023 (w/ Anna Shah, MD & Jennifer Simpson, MD)

BTK Inhibitors: The Next Wave in MS Treatment, 4/19/2023 (w/ Anthony Declusin, MD)

### University of Colorado Neurology Professor Rounds:

"A 61-year-old man with headache" – Isolated infratentorial PRES, 9/27/2019

"A 55-year-old woman with hemiparesis" – Primary cerebral amyloidoma, 11/22/2019

"An 85-year-old man with dyspnea" – Pembrolizumab-associated myasthenia gravis, 7/31/2020

### University of Colorado Neurology Research Retreat:

Arguments for Disease-modifying Therapy De-escalation in Multiple Sclerosis, 6/1/2022

### University of Colorado Neuroimmunology Division Conference:

BTK Inhibitors in Multiple Sclerosis, 3/4/2021

Remyelination Therapies: What's Next?, 7/21/2022

Leukodystrophies: Multiple Sclerosis Mimicry and Misdiagnosis, 1/19/2023

Alternative Dosing Strategies for anti-CD20 Disease-modifying Therapies, 3/16/2023

Radiologic Differentiation of Tumefactive Demyelination, 5/18/2023

## Extramural Presentations

---

- 1.) Acute Management of NMOSD. From Clinical Studies to the Real World: Sharing Clinical Experience in the Treatment of NMOSD. Aurora, CO. 11/2023.
- 2.) Use and Misuse of Stem Cell Treatments and Implications for Medical Tourism. Stem Cell Transplantation in Neurology: the Good, the Bad, and the Ugly. American Academy of Neurology Annual Meeting, Denver, CO, 4/2024.
- 3.) Metrics of Disability Accrual in Multiple Sclerosis. Novartis Multiple Sclerosis Education Event. Aurora, CO. 5/2024.

## Intramural Service

---

### University of Colorado Neurology Residency Program

Chief Resident, 7/2021-6/2022

Resident Selection Committee, 2022-2023, 2023-2024

Director, Didactic Neuroimmunology Block (12 hours of content), 7/2023-present

Director, Journal Club (monthly 1-hour sessions), 7/2023-7/2024

Director, Didactic Curriculum (oversight of didactics and journal club), 7/2024-present

### University of Colorado MD Program:

MD Admissions Interviewer, 2023-2024

BA/BS-MD Admissions Interviewer, 2023-2024

## Extramural Service

---

ACTRIMS fellowship webinar series, organizing committee, 2022-2023

American Academy of Neurology Annual Meeting, session monitor, Boston, MA, 4/2023

## Clinical Outreach

---

AHEC health screenings, National Western Stock Show, Denver, CO, volunteer, 1/2016

DAWN Clinic, Aurora, CO, volunteer physician, 5/2022-present (1 evening monthly)

## Educational Outreach

---

Denver Museum of Nature & Science, Brain Awareness Week, Denver, CO, 3/2016

Rio Grande Inn, lecture on Alzheimer's disease, La Jara, CO, 7/2016

Helmet Heads, TBI prevention outreach, Aurora, CO, 5/2017

National MS Society ECHO MS Mountain Hub, case presentation, 1/2023

Rocky Mountain MS Center, Conversations in MS, Pueblo, CO, 10/2023

National MS Society ECHO MS Mountain Hub, lecture, 3/2024

Rocky Mountain MS Center, Spring Education Summit, lecture and Q&A, 4/2024

## Media

---

- 1.) VJ Neurology. Raising awareness of the misuse of stem cell therapies in neurology. 4/2024.  
<https://www.vjneurology.com/video/cqbbxwldjr8-raising-awareness-of-the-misuse-of-stem-cell-therapies-in-neurology/>

## Honors

---

Summa cum laude, Arizona State University, 5/2010

Recognition for excellence on medical student evaluations, University of Colorado SOM, 8/2021

Extra Mile Award, University of Colorado Neurology Residency Program, 6/2022

Resident Research Award, University of Colorado Neurology Residency Program, 6/2022

Chief Resident Award, University of Colorado Neurology Residency Program, 6/2022

Recognition for high-performance on patient experience scores, UCHHealth, 7/2023

Al Anderson Teaching Award, University of Colorado Neurology Residency Program, 6/2024

## Financial Disclosures

---

Institutional payments: research from the Rocky Mountain MS Center, the Brotherton Foundation, Mowry Family, Biogen, Genentech, and the Michael J. Fox Foundation; honoraria from Amgen, Novartis, and Horizon Therapeutics.

Individual payments: consulting from TG Therapeutics and Genentech; honoraria from MedLink Neurology.

*Updated 6/2024*